Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris

NCT02616614 is registered in ClinicalTrials.gov with Actavis Inc. as lead sponsor.

NCT NCT02616614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris
Lead sponsor
Actavis Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2015
Completion date
November 30, 2015
Enrollment
862 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris